Background: The remarkable patency of internal mammary artery (MA) grafts compared to saphenous vein (SV) grafts has been related to different biological properties of the two blood vessels. We examined whether proliferation and apoptosis of vascular smooth muscle cells (VSMC) from human coronary artery bypass vessels differ according to patency rates. Methods and Results: Proliferation rates to serum or platelet-derived growth factor (PDGF)-BB were lower in VSMC from MA than SV. Surface expression of PDGF β-receptor was slightly lower, while that of α-receptor was slightly higher in MA than SV. Cell cycle distribution, expression of cyclin E, cdk2, p21, p27, p57, and cdk2 kinase activity were identical in PDGF-BB-stimulated cells from MA and SV. However, apoptosis rates were higher in MA than SV determined by lactate dehydrogenase release, DNA fragmentation, and Hoechst 33258 staining. Moreover, caspase inhibitors (Z-VAD-fmk, Boc-D-fmk) abrogated the different proliferation rates of VSMC from MA versus SV. Western blotting and GSK3-β kinase assay revealed lower Akt activity in VSMC from MA versus SV, while total Akt expression was identical. Adenoviral transduction of a constitutively active Akt mutant abrogated the different proliferation rates of VSMC from MA versus SV. Conclusions: Higher apoptosis rates due to lower Akt activity rather than different cell cycle regulation account for the lower proliferation of VSMC from MA as compared to SV. VSMC apoptosis may protect MA from bypass graft disease.

Keywords:
Apoptosis, Atherosclerosis, Cell cycle, Proliferation, Signal transduction
1.
Loop FD, Lytle BW, Cosgrove DM, Stewart RW, Goormastic M, Williams GW, Golding LA, Gill CC, Taylor PC, Sheldon WC: Influence of the internal-mammary artery graft on 10-year survival and other cardiac events. N Engl J Med 1986;314:1–6.
2.
Loscalzo J: Vascular matrix and vein graft failure. Circulation 2000;101:221–223.
3.
Li S, Fan YS, Chow LH, Van Den Diepstraten C, van Der Veer E, Sims SM, Pickering JG: Innate diversity of adult human arterial smooth muscle cells: cloning of distinct subtypes from the internal thoracic artery. Circ Res 2001;89:517–525.
4.
Ross R: Platelets, platelet-derived growth factor, growth control, and their interactions with the vascular wall. J Cardiovasc Pharmacol 1985;7:186–190.
5.
Rössig L, Dimmeler S, Zeiher AM: Apoptosis in the vascular wall and atherosclerosis. Basic Res Cardiol 2001;96:11–22.
6.
Han DK, Haudenschild CC, Hong MK, Tinkle BT, Leon MB, Liau G: Evidence for apoptosis in human atherogenesis and in a rat vascular injury model. Am J Pathol 1995;147:267–277.
7.
Bennett MR: Vascular smooth muscle cell apoptosis – a dangerous phenomenon in vascular disease. J Clin Basic Cardiol 2000;3:63–65.
8.
Rechler MM, Podskalny JM, Goldfine ID, Wells CA: DNA synthesis in human fibroblasts: stimulation by insulin and by nonsuppressible insulin-like activity. J Clin Endocrinol Metab 1974;39:512–521.
9.
Tanner FC, Yang ZY, Duckers E, Gordon D, Nabel GJ, Nabel EG: Expression of cyclin-dependent kinase inhibitors in vascular disease. Circ Res 1998;82:396–403.
10.
Tanner FC, Meier P, Greutert H, Champion C, Nabel EG, Lüscher TF: Nitric oxide modulates expression of cell cycle regulatory proteins: a cytostatic strategy for inhibition of human vascular smooth muscle cell proliferation. Circulation 2000;101:1982–1989.
11.
Tokunou T, Shibata R, Kai H, Ichiki T, Morisaki T, Fukuyama K, Ono H, Iino N, Masuda S, Shimokawa H, Egashira K, Imaizumi T, Takeshita A: Apoptosis induced by inhibition of cyclic AMP response element-binding protein in vascular smooth muscle cells. Circulation 2003;108:1246–1252.
12.
Ming XF, Viswambharan H, Barandier C, Ruffieux J, Kaibuchi K, Rusconi S, Yang Z: Rho GTPase/Rho kinase negatively regulates endothelial nitric oxide synthase phosphorylation through the inhibition of protein kinase B/Akt in human endothelial cells. Mol Cell Biol 2002;22:8467–8477.
13.
Brazil DP, Hemmings BA: Ten years of protein kinase B signalling: a hard Akt to follow. Trends Biochem Sci 2001;6:657–664.
14.
Sherr CJ: G1 phase progression: cycling on cue. Cell 1994;79:551–555.
15.
Tanner FC, Boehm M, Akyürek LM, San H, Yang ZY, Nabel GJ, Nabel EG: Differential effects of the cyclin-dependent kinase inhibiors p27Kip1, p21Cip1, and p16Ink4 on vascular smooth muscle cell proliferation. Circulation 2000;101:2022–2025.
16.
Yang Z, Oemar BS, Carrel T, Kipfer B, Julmy F, Lüscher TF: Different proliferative properties of smooth muscle cells of human arterial and venous bypass vessels. Circulation 1998;97:181–187.
17.
Bennett MR: Apoptosis in the cardiovascular system. Heart 2002;87:480–487.
18.
Kockx MM, Herman AG: Apoptosis in atherosclerosis: beneficial or detrimental? Cardiovasc Res 2000;45:736–746.
19.
Jawien A, Bowen-Pope DF, Lindner V, Schwartz SM, Clowes AW: Platelet-derived growth factor promotes smooth muscle migration and intimal thickening in a rat model of balloon angioplasty. J Clin Invest 1992;89:507–511.
20.
Takahashi T, Taniguchi T, Konishi H, Kikkawa U, Ishikawa Y, Yokoyama M: Activation of Akt/protein kinase B after stimulation with angiotensin II in vascular smooth muscle cells. Am J Physiol 1999;276:H1927–H1934.
21.
Wong AP, Nafiseh N, Strauss BH: In vitro differences between venous and arterial-derived smooth muscle cells: potential modulatory role of decorin. Cardiovasc Res 2005;65:702–710.
© 2006 S. Karger AG, Basel
2006
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.